Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

709
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
709

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction: Interventions against disability in frail older adults: Lessons learned from clinical trials.

The journal of nutrition, health & aging·2026
Same author

Corrigendum to "Current and investigational medications for the treatment of sarcopenia" [Metabolism 2023;149:155597].

Metabolism: clinical and experimental·2026
Same author

Transversal suture of the rectus abdominis muscle in DIEP harvesting to include more than one perforator: Technical note.

Annales de chirurgie plastique et esthetique·2025
Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025
Same author

Editorial: ICOPE Healthy Longevity Integrative Preventive Care, Alzheimer's Disease Prevention and Early Diagnosis.

The journal of prevention of Alzheimer's disease·2024
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024

Related Experiment Video

Updated: Apr 5, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.2K

Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.

B Vellas1, R Bateman2, K Blennow3

  • 1UMR1027 Inserm, F-31073, Toulouse, France ; University of Toulouse III, F-31073, France ; Gerontopole Toulouse, Toulouse University Hospital, F-31000, Toulouse, France.

The Journal of Prevention of Alzheimer'S Disease
|August 7, 2015
PubMed
Summary
This summary is machine-generated.

Identifying effective outcome measures for Alzheimer's disease (AD) trials in clinically normal individuals is crucial. Novel composite, functional, and biomarker assessments show promise for detecting early AD progression.

Keywords:
Pre-dementia Alzheimer’s diseasebiomarkerscognitive outcome assessmentsfunctional outcome assessments

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.9K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.2K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.9K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K

Area of Science:

  • Neurology
  • Clinical Trials
  • Biomarkers

Background:

  • Alzheimer's disease (AD) treatment trials targeting the pre-dementia stage require sensitive outcome measures for clinically normal individuals.
  • Assessing disease progression in early stages is vital for therapeutic development.

Purpose of the Study:

  • To discuss existing and novel outcome assessments for pre-dementia AD trials.
  • To identify measures capable of detecting subtle changes in individuals with early-stage Alzheimer's disease.

Main Methods:

  • Convened the EU/US CTAD Task Force, an international collaboration.
  • Reviewed composite cognitive and functional measures.
  • Considered patient-reported outcomes and novel biomarkers (CSF and imaging).

Main Results:

  • Composite measures of episodic memory, executive function, global cognition, and function show sensitivity in pre-dementia stages.
  • Functional measures involving real-life tasks capture clinically meaningful early changes.
  • Patient-reported outcomes and biomarkers show potential for early AD detection.

Conclusions:

  • Several novel outcome measures demonstrate promise for assessing Alzheimer's disease progression in pre-dementia trials.
  • Further validation studies are needed for these measures in the target population.
  • Many promising measures are being incorporated into ongoing and planned clinical trials.